CDR3 Therapeutics
CDR3 Therapeutics is a pre-revenue biotech developing a patented stem cell-based gene therapy platform designed to create self-renewing gene-targeted T cells for treating leukemia, lymphoma, and other virus-associated cancers. Founded in 2017 and based in El Segundo, California.
- Company typePrivate
- Founded2017
- HeadquartersEl Segundo, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What CDR3 Therapeutics does
CDR3 Therapeutics is a privately held, pre-revenue biotechnology company founded in 2017 and headquartered at 710 W. Sycamore Ave., El Segundo, California. The company develops stem cell-based gene immunotherapies intended to treat chronic viral infections and virus-associated cancers, with an initial therapeutic focus on leukemia and lymphoma. Its central thesis is that conventional gene-modified T cell therapies produce only short-lived clinical effects, whereas CDR3's stem-cell-based approach aims to establish a self-renewing source of gene-targeted immune cells in the body, producing durable immunity.
The company's product surface is a single unified platform: the CDR3 Stem Cell Gene Therapy Technology, for which a patent is on file (filed/pending). Public materials describe the technology as a novel method architecture leveraging stem cells to engineer persistent, gene-targeted T cell responses. The company has no commercial products, no disclosed customers, no disclosed partnerships, no disclosed management team, no funding rounds on record, and no regulatory milestones beyond the IP filing. Public-facing assets are limited to a company website, an executive summary PDF dated June 2021, and a YouTube explainer video.
CDR3's business model is investment-funded biotech R&D rather than commercial sales: there is no pricing, no recurring revenue, and no go-to-market infrastructure. The company employs 1-10 people and is actively soliciting outside capital to advance its technology toward clinical development. Future revenue mechanics (licensing, partnership milestones, or eventual product commercialization) are not yet defined in the available source data.
CDR3 Therapeutics firmographics
Firmographics- Name
- CDR3 Therapeutics
- Legal name
- CDR3 Therapeutics
- Website
- https://cdr3therapeutics.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CDR3 Therapeutics is a pre-revenue biotech developing a patented stem cell-based gene therapy platform designed to create self-renewing gene-targeted T cells for treating leukemia, lymphoma, and other virus-associated cancers. Founded in 2017 and based in El Segundo, California.
- Ownership category
- akta.pro rank
CDR3 Therapeutics industry classification
Industry- Product category
- Cancer Gene Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- CAR-T & TCR-T Therapies (HLAAABAC)
Keywords
Where CDR3 Therapeutics is headquartered
LocationHeadquarters
- HQ city
- El Segundo
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CDR3 Therapeutics business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Biopharmaceutical Development: Pre-revenue biotech company developing a novel gene therapy treatment for cancer. No commercial revenue streams established yet as the technology is still in development phase.
Go-to-market motion1 record
Marketing channels1 record
CDR3 Therapeutics product offering
Product offeringCore offering
CDR3 Therapeutics develops a patented stem cell-based gene therapy platform that creates a self-renewing source of gene-targeted immune (T) cells in the body to provide long-lasting immunity against viruses and cancers. The technology specifically targets leukemia, lymphoma, and virus-associated cancers, addressing the short-lived effect limitation of conventional gene therapies by leveraging stem cells for durable immune responses.
Product overview
CDR3 Therapeutics offers a single unified therapeutic product — their patented stem cell-based gene therapy technology. This core technology platform uses stem cells to create a self-renewing source of gene-targeted T cells, providing long-lasting immunity against cancers (leukemia and lymphoma) and viruses. Unlike conventional T cell therapies with short-lived effects, CDR3's approach leverages stem cells to build durable immune responses.
Differentiator
Problem solved
Functional benefit
Products and services
- CDR3 Stem Cell Gene Therapy Technology Patented stem cell-based gene therapy platform that creates a self-renewing source of gene-targeted immune (T) cells inside the body to provide long-lasting immunity against viruses and cancers, with primary indications in leukemia, lymphoma, and virus-associated cancers. Intended for cancer patients who would otherwise face short-lived effects from conventional gene therapies.
Companies that use CDR3 Therapeutics
Customer profileSegments1 record
Ideal customer profiles1 record
CDR3 Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
CDR3 Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
CDR3 Therapeutics competitors and assessment
Company assessmentDirect peers
- Adaptimmune Therapeutics: Clinical-stage company developing TCR-T cell therapies for solid tumors and hematologic cancers. Directly comparable to CDR3's gene-targeted T cell approach in oncology.
- Allogene Therapeutics: Pioneering allogeneic CAR-T cell therapies for cancer. Comparable gene-modified T cell platform focused on hematologic malignancies, similar to CDR3's leukemia/lymphoma focus.
- Fate Therapeutics: Develops iPSC-derived off-the-shelf cell therapies including NK and T cell products for cancer. Comparable in pursuing durable, renewable immune cell sources — conceptually adjacent to CDR3's stem cell approach.
- Cellectis: Clinical-stage gene-edited allogeneic CAR-T company (UCART programs). Comparable gene-modified cell therapy platform targeting leukemia and lymphoma.
- Precision BioSciences: Develops allogeneic CAR-T cell therapies using ARCUS gene editing. Comparable gene-modified T cell approach targeting hematologic cancers.
- Caribou Biosciences: Clinical-stage allogeneic CAR-T and NK cell therapy company using CRISPR-edited immune cells. Direct peer in gene-edited cell therapy for oncology.
Broad incumbents
- CRISPR Therapeutics: Gene-edited cell therapies including approved Casgevy (CTX001) for sickle cell disease. Comparable gene-modified cell therapy platform with both oncology and broader disease scope.
- Iovance Biotherapeutics: Approved tumor-infiltrating lymphocyte (TIL) therapy for solid tumors. Broader cell therapy incumbent relevant to CDR3's cancer immunotherapy positioning.
- Gilead Sciences (Kite Pharma): Approved CAR-T franchise (Yescarta, Tecartus) plus early-stage cell therapy R&D. Established leader in hematologic cell therapy against which CDR3 would compete.
- Novartis (Kymriah / T-Charge platform): Major pharma with approved CAR-T (Kymriah) and next-gen autologous cell therapy manufacturing platform. Sets the competitive bar in CD19-targeted T cell therapy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat1 record
Key risks6 records
Key highlights4 records
Customer concentration
CDR3 Therapeutics social profiles
Digital presenceCDR3 Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
CDR3 Therapeutics leadership team
Management profileNumber of profiles
CDR3 Therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CDR3 Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CDR3 Therapeutics
What does CDR3 Therapeutics do?
CDR3 Therapeutics develops a patented stem cell-based gene therapy platform that creates a self-renewing source of gene-targeted immune (T) cells in the body to provide long-lasting immunity against viruses and cancers. The technology specifically targets leukemia, lymphoma, and virus-associated cancers, addressing the short-lived effect limitation of conventional gene therapies by leveraging stem cells for durable immune responses.
Is CDR3 Therapeutics a public or private company?
CDR3 Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was CDR3 Therapeutics founded?
CDR3 Therapeutics was founded in 2017. It employs 1 to 10 people.
Where is CDR3 Therapeutics based?
CDR3 Therapeutics is headquartered in El Segundo, United States, in the North America region.
How does CDR3 Therapeutics make money?
One revenue line is on record: biopharmaceutical Development.
Who are CDR3 Therapeutics's main competitors?
Direct peers on record are Adaptimmune Therapeutics, Allogene Therapeutics, Fate Therapeutics, Cellectis, Precision BioSciences and Caribou Biosciences. Broad incumbents are CRISPR Therapeutics, Iovance Biotherapeutics, Gilead Sciences (Kite Pharma) and Novartis (Kymriah / T-Charge platform).
Does CDR3 Therapeutics have an API?
No public API is recorded for CDR3 Therapeutics.
What industry is CDR3 Therapeutics in?
CDR3 Therapeutics's product category is Cancer Gene Therapy. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 541714 and its SIC code is 2834.